Fig. 5

Cancer cell-derived EVs delivering miR-744 inhibits the development of NSCLC by targeting SUV39H1 in vitro. a Expression of SUV39H1 determined by RT-qPCR in cancer and adjacent normal tissues. (* p < 0.05, vs. adjacent normal tissues). b and c RT-qPCR (b) and western blot analysis (c) evaluating the knockdown efficiency of 3 siRNAs targeting SUV39H1 in A549 and H460 cells (* p < 0.05, vs. A549 and H460 cells transfected with si-NC). d Expression of miR-744 determined by RT-qPCR in si-SUV39H1-1-transfected A549 and H460 cells treated with BEAS-2B- and H1299-derived EVs. e and f RT-qPCR (e) and western blot analysis (f) measuring the expression of SUV39H1 in si-SUV39H1-1-transfected A549 and H460 cells treated with BEAS-2B- and H1299-derived EVs. g–i CCK-8 assay (g), colony formation assay (h), and cell cycle analysis (i) in si-SUV39H1-1-transfected A549 and H460 cells treated with BEAS-2B-, and H1299-derived EVs (* p < 0.05, vs. BEAS-2B-derived EVs, si-NC-transfected A549 and H460 cells treated with BEAS-2B-derived EVs; # p < 0.05, vs. si-NC-transfected A549 and H460 cells treated with H1299-derived EVs). j Western blots of SUV39H1 protein and its quantitation in tumor tissues of mice injected with A549 cells treated with BEAS-2B-, H522- and H1299-derived EVs (* p < 0.05, vs. mice injected with A549 cells treated with BEAS-2B-derived EVs). Data are summarized as mean ± standard deviation. Data from two groups were compared using unpaired t-test and data from multiple groups were compared by one-way ANOVA with Tukey's post hoc tests. Data obtained at different time points were compared by Bonferroni-corrected repeated measures ANOVA. Mice: n = 8/group. Each experiment was repeated three times